Differences in complications, cardiovascular risk factor, and diabetes management among participants enrolled at veterans affairs (VA) and non-VA medical centers in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE)

Highlights

• GRADE enrolled participants with type 2 diabetes treated with metformin enrolled at VA and non-VA clinical centers.

• Participants enrolled at VA and non-VA centers had different baseline characteristics and risk factor management.

• These differences reflected the background population and management protocols prevalent at these two categories of clinical centers.

• VA participants had similar HbA1c and weight as non-VA participants.

• VA participants had higher rates of hypertension, hyperlipidemia, and cardiovascular disease compared to non-VA participants.

• VA site participants were generally more likely than non-VA participants to have guideline-concordant CVD risk factor management.

Abstract

Aims

We evaluated differences in participants with type 2 diabetes (T2DM) enrolled in the GRADE study at VA vs non-VA sites, focusing on cardiovascular risk factors and rates of diabetes care target achievements.

Methods

We compared baseline characteristics between participants at VA (n = 1216) and non-VA (n = 3831) sites, stratifying analyses by cardiovascular disease (CVD) history.

Results

VA and non-VA participants had similar diabetes duration (4.0 years), HbA1c (7.5%), and BMI (34 kg/m²); however, VA participants had more individuals ≥ 65 years (37.3% vs 19.8%, p < 0.001), men (90.0% vs 55.2%, p < 0.001), hypertension (75.8% vs 63.6%, p < 0.001), hyperlipidemia (76.6% vs 64.6%, p < 0.001), current smokers (19.0% vs 12.1%, p < 0.001), nephropathy (20.4% vs 17.0%, p < 0.05), albuminuria (18.4% vs 15.1%, p < 0.05), and CVD (10.4% vs 5.2%, p < 0.001). In those without CVD, more VA participants were treated with lipid (70.8% vs 59.5%, p < 0.001) and blood pressure (74.9% vs 65.4%, p < 0.001) lowering medications, and had LDL-C < 70 mg/dl (32.9% vs 24.2%, p < 0.05). Among those with CVD, more VA participants had BP < 140/90 (80.2% vs 70.1%, p < 0.05) after adjusting for demographics.

Conclusion

GRADE participants at VA sites had more T2DM complications, greater CVD risk and were more likely to be treated with medications to reduce it, leading to more LDL-C at goal than non-VA participants, highlighting differences in diabetes populations and care.

Introduction

More than 30 million Americans have diabetes, of which 90% to 95% have type 2 diabetes (T2D) [1]. Type 2 diabetes is heterogeneous in terms of both pathophysiology [2], [3] and treatment [4], [5], [6], [7]. The U.S. Department of Veterans Affairs (VA) reports that nearly one in four men and women who served in the US armed forces have diabetes [8], [9]. Roughly 18 million individuals, or 7% of the US population, were veterans of the US Armed Forces in 2018 [10]. Nine million receive care in the VA through 170 VA Medical Centers and more than 1000 outpatient clinics [11]. Compared to the general population, veterans have higher rates of obesity [12], tend to be older, have lower income, and have limited access to high-quality, healthy food. Each of these characteristics and social determinants of health are associated with greater diabetes risk and an increased frequency of diabetes-related complications. Conversely, by providing standard care to all veterans, the VA system has reduced many racial and ethnic health care disparities [13].

To standardize care, the VA system has employed a variety of quality improvement initiatives and collaboratives, as well as innovative programs. As an integrated health care system, the VA has implemented several simultaneous, national-level quality of care improvement strategies including leveraging a single electronic health record (EHR), unified nationwide guidelines, and effective performance monitoring. With respect to diabetes, the VA has specific diabetes care guidelines that are aligned with other national guidelines and has access to extensive clinical decision support tools [14] along with the implementation of the patient-aligned care team (PACT) primary care model and other initiatives such as adoption of the Choosing Wisely campaign to avoid unnecessary medical testing [15], [16].

The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) is a 36-clinical center national comparative effectiveness trial which was conducted to identify the most effective second glucose-lowering drug when added to metformin, for T2D over time. Ten of the 36 clinical centers were based at VA Medical Centers or had VA subsites, while the other sites represented a mix of academic, community, and health maintenance organization practices. All participants underwent identical screening processes and met identical eligibility criteria. Nevertheless, we seek to evaluate if there were substantial population differences comparing VA to non-VA sites. We also assessed differences in medical management at baseline since the GRADE cohort offered an opportunity to examine a snapshot of current diabetes care across different care settings. Specifically, this paper aims to evaluate whether GRADE participants’ baseline cardiovascular risk factors and risk factor management differed between participants enrolled at VA and non-VA clinical sites, and according to sociodemographic factors. We hypothesized that, after adjusting for baseline demographic differences, given quality improvement efforts, participants enrolled at VA sites would be more likely to be treated according to established guidelines and to meet standard diabetes care parameters than non-VA site participants.